Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.
Press releases published on May 8, 2025

Nanox to Report First Quarter 2025 Financial Results on May 22, 2025
PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, …

AVITA Medical Reports First Quarter 2025 Financial Results
VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025 …

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of …

Metsera to Present at Bank of America 2025 Global Healthcare Conference
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit …

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to …

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
– Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed …

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in …

Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results
SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter …

Teknova Reports First Quarter 2025 Financial Results
First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., …

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
Strong execution and progress across pipeline with multiple key data read outs expected in 2025 Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in June Phase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU …

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual …

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity model In vitro data reported from new preclinical study …

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH- …

Jushi Holdings Inc. Reports First Quarter 2025 Financial Results
Retail-First Growth Strategy Continues with 40 Operational Locations Nationwide at Quarter-End and Five Additional Stores Expected to Open by Year-End Strengthened Balance Sheet Through Strategic Transactions to Support Continued Expansion Net Loss of $17. …

Pacira BioSciences Reports First Quarter 2025 Financial Results
-- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of …

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European …

DLH to Continue Providing R&D and Advanced Technology Services to the Telemedicine and Advanced Technology Research Center
ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security, today …

FoLix By Lumenis Recognized for Dermatology Innovation in 2025 MedTech Breakthrough Awards Program
LOS ANGELES, May 08, 2025 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market, today announced …

MEDIAIPLUS leads data-driven solutions to close clinical trial information gaps
MEDIAIPLUS uses AI to close clinical trial info gaps, offering data tools that match CROs, aid researchers, and support global pharma with smart solutions. PANGYO, GYEONGGI-DO, SOUTH KOREA, May 8, 2025 /EINPresswire.com/ -- Founded in 2019, MEDIAIPLUS …